^
Association details:
| Biomarker: | TROP2 positive |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | ABN202 (EGFR inhibitor, IFN stimulant, TROP-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4430 / 16 - Sacituzumab-Interferon beta mutein fusion protein, ABN202 (anti Trop2-interferon beta mutein), is a potent therapeutics for Trop-2-positive urothelial cancer
Published date:
03/15/2023
Excerpt:
Our results revealed that ABN202 directly inhibited proliferation and activates the apoptosis-related signaling mechanisms via Type 1 IFN signaling, showing better efficacy than either anti Trop2 antibody (sacituzumab) or ABN102 alone….We evaluated the direct and indirect anti-cancer efficacy of ABN202 (anti Trop2-interferon-beta mutein) in Trop2-positive urothelial cancer. Our results support that ABN202 is a potent drug candidate in Trop2-positive urothelial cancer by directly inhibiting tumor growth and activating anti-cancer immune responses...
